NIH Record - National Institutes of Health

Trial Opens for Potential Universal Flu Vaccine

Head shot of Dr. Matthew Memoli
Dr. Matthew Memoli

NIH investigators have begun testing a universal influenza vaccine designed to protect against a wide range of seasonal flu viruses and those with pandemic potential. A phase 1 clinical trial of this novel flu vaccine has begun inoculating healthy adult volunteers at the Clinical Center. 

The placebo-controlled trial will test the safety of a candidate vaccine, BPL-1357, and its ability to prompt immune responses. The vaccine candidate was developed by NIAID researchers. The single-site trial, led by NIAID investigator Dr. Matthew Memoli, can enroll up to 100 people ages 18 to 55 years. 

The BPL-1357 candidate influenza vaccine performed well in preclinical studies and now will be tested in people. BPL-1357 is a whole-virus vaccine made up of four strains of non-infectious, chemically inactivated, low-pathogenicity avian flu virus. 

Dr. Jeffery Taubenberger in front of colorful double helix and bookshelf
Dr. Jeffery Taubenberger

A study in animals led by NIAID investigator Dr. Jeffery Taubenberger found that all mice receiving 2 doses of BPL-1357 vaccine delivered either intramuscularly or intranasally survived later exposure to lethal doses of each of 6 different influenza virus strains, including subtypes that were not included in the vaccine. Similar results were obtained in challenge experiments with BPL-1357-vaccinated ferrets.

In the phase 1 trial, volunteers will be randomized in a 1:1:1 ratio into 3 groups and will receive 2 doses of placebo or vaccine spaced 28 days apart. 

Group A participants receive BPL-1357 intramuscularly along with intranasal saline placebo; group B will receive doses of the candidate vaccine intranasally along with intramuscular placebo; volunteers in group C receive intramuscularly and intranasally delivered placebo at both visits to the clinic. Neither the study clinicians nor the volunteers know the group assignments. 

Gloved hands hold a syringe to a patient's forearm.
Volunteer in trial of candidate universal flu vaccine BPL-1357 receives an intramuscular injection.

Photo:  NIAID

“With the BPL-1357 vaccine, especially when given intranasally, we are attempting to induce a comprehensive immune response that closely mimics immunity gained following a natural influenza infection,” said Memoli. “This is very different than nearly all other vaccines for influenza or other respiratory viruses, which focus on inducing immunity to a single viral antigen and often do not induce mucosal immunity.

“Our study will examine the safety of BPL-1357,” he added, “and also will allow us to assess the importance of mucosal immunity against flu and whether a strategy of inducing both the cellular and antibody arms of the immune system can provide broader protection against the ever-changing influenza virus.”   

The NIH Record

The NIH Record, founded in 1949, is the biweekly newsletter for employees of the National Institutes of Health.

Published 25 times each year, it comes out on payday Fridays.

Associate Editor: Dana Talesnik
Dana.Talesnik@nih.gov (link sends e-mail)

Assistant Editor: Eric Bock
Eric.Bock@nih.gov (link sends e-mail)

Staff Writer: Amber Snyder
Amber.Snyder@nih.gov (link sends e-mail)